George Medicines: creating affordable cardio-metabolic disease treatments

Main content area
Publication Date: 
November 2020
Case study from: Industry Innovation and Science Australia annual reports

George Medicines is a biopharmaceutical startup company backed by Brandon Capital Partners. 

George Medicine develops treatments designed to improve clinical outcomes in patients with cardio-metabolic diseases, such as:

  • heart disease
  • hypertension
  • diabetes

Cardio-metabolic diseases are the leading causes of premature death and disability worldwide.

Globally, more than 2 billion people suffer from chronic disease, such as:

  • hypertension
  • diabetes
  • heart disease

Fifteen million people between the ages of 30 and 69 die from non-communicable diseases each year. 

Many of these people remain undiagnosed or are on inappropriate treatment. Some are unlikely to receive any treatment at all. 

George Medicines focus on novel doses and combinations of existing medicines. Innovative research from the renowned George Institute in Sydney directed their approach. 

George Medicines is creating affordable treatments. The treatments will ultimately improve disease treatment. This will provide a higher quality of life for patients. 

These new medications promise to be more effective than current approaches. They will also reduce the number of pills patients are required to take. Together, this makes it easier for patients to achieve their treatment goals. 

George Medicine’s products will serve the medical needs of a very large number of people in Australia. It will also help overseas countries, in both the developed and developing worlds. 

 “George Medicines has a real and tantalising potential to revolutionise the ease of use, accessibility and affordability of medicines for cardiovascular and metabolic disease, in both the developed and developing worlds" said Dr Ingmar Wahlqvist, Director at George Medicines and Senior Investment Manager at Brandon Capital. 

Using a combination of proven medicines lowers the technical risk. It also shortens the timeframes and costs of development. The novel combination of medicines and dosages also lends itself to patent protection. This makes the products relatively resistant to competitive pressure. 

Brandon Capital Partners manages seed and venture capital investment. It supports the development and international growth of Australian and New Zealand life science companies. 

Brandon Capital Partners has committed $20 million in investment to George Medicines. They made the investment through the Medical Research Commercialisation Fund-Biomedical Translation Fund (MRCF BTF),

The MRCFBTF consists of at least equal parts Commonwealth and industry funding. This commitment comprises $10 million from the Commonwealth and $10 million from the private sector. 

George Health has matched MRCF BTF’s investment. It was done with support from BUPA Innovations and Federation Asset Management. 

The total financial commitment is $40 million. This is one of Australia’s largest-ever public private health partnerships.

 “We’re delighted that such a strong group of investors shares our impact vision and are putting their money where it will make a difference to the health of millions of people, as well as delivering globally competitive financial returns” said Staph Leavenworth Bakali Director of George Medicines and CEO of George Health Enterprises, Co-Investor in George Medicines. 

Read more